AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36108308
Drug: Rondaptivon pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rondaptivon pegol (6 doses)
Trial: 36108661
Drug: Selpercatinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selpercatinib (160 mg twice daily)
Trial: 36109029
Drug: Digital exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital exposure treatment
Trial: 36109430
Drug: Immediate drug
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate drug withdrawal after delivery
Trial: 36109430
Drug: Delayed drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed drug withdrawal at 6 weeks after delivery
Trial: 36109652
Drug: Microencapsulated watermelon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microencapsulated watermelon rind (MWR) 30 g containing 4 g of L-citrulline
Trial: 36110277
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine (acupuncture, Chinese herbs, repeated transcranial magnetic stimulation)
Trial: 36110277
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (basic treatment, general nursing care, exercise therapy)
Trial: 36110295
Drug: Intermittent PEG-IFNα
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent PEG-IFNα therapy
Trial: 36110295
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment HBsAg response
Trial: 36110959
Drug: E150 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E150 (150 mg erlotinib for non-smokers)
Trial: 36110959
Drug: E300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E300 (300 mg erlotinib for smokers)
Trial: 36110959
Drug: Early in-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early in-treatment [18]FDG PET/CT
Trial: 36111288
Drug: Oral antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotic (OAP) treatment
Trial: 36111839
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy initiated with a delay (≥8 weeks after surgical resection)
Trial: 36111839
Drug: Timely initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely initiation of adjuvant chemotherapy
Trial: 36113242
Drug: FCN-159 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-159 (12 mg QD)
Trial: 36113242
Drug: FCN-159 (≥6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-159 (≥6 mg QD)
Trial: 36113895
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (T-VEC) followed by intratumoral injection of CD1c (BDCA-1)
Trial: 36113946
Drug: Structural harm
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural harm reduction strategies (e.g., syringe service programmes)
Trial: 36113962
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic acid (MPA) treatment
Trial: 36113962
Drug: MPA treatment
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA treatment (adjusted analysis)
Trial: 36114102
Drug: dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dupilumab 300 mg every 2 weeks up to 96 weeks
Trial: 36115673
Drug: Neoadjuvant SBRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant SBRT (8 Gy × 3 fractions) plus PD-1 inhibitor (tislelizumab) administered in two cycles with a 3-week interval before surgery.
Trial: 36115674
Drug: REVEAL(OT) intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: REVEAL(OT) intervention added to standard multidisciplinary chronic pain treatment
Trial: 36115931
Drug: Anti-PD-1 combination
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 combination therapy
Trial: 36115947
Drug: erenumab 70-140
RxNorm normalized name: erenumab-aooe 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erenumab 70-140 mg s.c. every 28 days for one year
Trial: 36115980
Drug: Simvastatin, L-arginine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, L-arginine, and tetrahydrobiopterin
Trial: 36116169
Drug: Anlotinib combined
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib combined with platinum-etoposide (chemotherapy)
Trial: 36116288
Drug: Norepinephrine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine administration during PLR
Trial: 36116293
Drug: remedē System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remedē System Therapy (transvenous phrenic nerve stimulation)
Trial: 36116506
Drug: Anti-CEL IgG
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CEL IgG and IgA antibodies in patients with HS
Trial: 36116866
Drug: Abundant microaspiration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abundant microaspiration (positive pepsin A ≥ 6.25 ng/mL)
Trial: 36117003
Drug: mRNA COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)
Trial: 37031282
Drug: mRNA COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA COVID-19 vaccines
Trial: 36117166
Drug: Post-direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-direct-acting antiviral agent HCC
Trial: 36117973
Drug: Low-dose dexmedetomidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexmedetomidine (0.1 to 0.2 μg/kg/h)
Trial: 36118751
Drug: Sugar-sweetened soda
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-sweetened soda (1 L/day)
Trial: 36119522
Drug: mDCF (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mDCF (docetaxel 40 mg/m², cisplatin, and 5-fluorouracil) followed by chemoradiotherapy
Trial: 36119641
Drug: cCRT (concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cCRT (concurrent chemoradiotherapy)
Trial: 36119641
Drug: EGFR-TKI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR-TKI monotherapy
Trial: 36119669
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin A (BoNT-A) treatment
Trial: 36120090
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA vaccine (30 μg), administered in two doses intramuscularly, 21 days apart
Trial: 36120713
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard outpatient treatment)
Trial: 36120850
Drug: Salvage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiation therapy (sRT) with or without 2 years of Bicalutamide
Trial: 36121244
Drug: Pharmacomechanical catheter-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacomechanical catheter-directed thrombolysis (PM-CDT) using the Bashir endovascular catheter with 7 mg tPA infused over 5 hours.
Trial: 36121499
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (EC-ASA)
Trial: 36121499
Drug: Plain aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aspirin (P-ASA)
Trial: 36121707
Drug: ARP strategy
RxNorm normalized name: erythromycin stearate Oral Suspension [Arpimycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARP strategy (LSM < 1.805 m/s or SSM < 2.445 m/s and PLT > 110 × 10^9/L)
Trial: 36122888
Drug: Culprit drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culprit drug identification through combined skin testing, in vitro testing, or drug provocation tests.
Trial: 36123069
Drug: Rapid serological
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2
Trial: 36123169
Drug: Opioid vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid vaccines
Trial: 36123697
Drug: TransCon TLR7/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon TLR7/8 Agonist
Trial: 36124180
Drug: HLX04-O intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX04-O intravitreal injections at a dose of 1.25 mg/0.05 mL every four weeks
Trial: 36124180
Drug: HLX04-O intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX04-O intravitreal injections
Trial: 36124767
Drug: Optimal Medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical Treatment
Trial: 36124872
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy at discharge
Trial: 36124924
Drug: Talazoparib 1
RxNorm normalized name: talazoparib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib 1 mg/day (0.75 mg/day for moderate renal impairment)
Trial: 36125116
Drug: Brain-computer interface
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain-computer interface (BCI) used to control a virtual hand, specific details on dosage and duration not available.
Trial: 36125263
Drug: Durvalumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab + Metformin
Trial: 36125356
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of qSOFA and IMX-SEV-2
Trial: 36125356
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IMX-SEV-2 and qSOFA
Trial: 36126298
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill adherence
Trial: 36126315
Drug: Compression therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy, details on dosage and duration not available.
Trial: 36127767
Drug: Pemigatinib 13.5
RxNorm normalized name: pemigatinib 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemigatinib 13.5 mg oral once daily (3-week cycle; 2 weeks on, 1 week off)
Trial: 36129032
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral anticoagulants
Trial: 36129273
Drug: Factor Xa
RxNorm normalized name: Anti factor Xa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor Xa inhibitor use
Trial: 36129688
Drug: Apremilast, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast, 30 mg, twice daily
Trial: 36129839
Drug: Preference for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference for testing when offered hypothetical CHIP treatment
Trial: 36129967
Drug: NJH395 (Anti-HER2-TLR7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NJH395 (Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate)
Trial: 36130137
Drug: Acupuncture treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment, details on dosage and duration not available.
Trial: 36130401
Drug: CRP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP and IL-6 combination
Trial: 36130693
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with doses of 60 to 72 Gy in 2 Gy fractions
Trial: 36131349
Drug: General floor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General floor treatment
Trial: 36131349
Drug: ICU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICU treatment
Trial: 36131934
Drug: CAR-T-cell therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T-cell therapy
Trial: 36133827
Drug: Prescription opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription opioid misuse (POM)
Trial: 36136180
Drug: Computer-guided buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-guided buccal cortical plate separation
Trial: 36136294
Drug: Socazolimab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socazolimab (5 mg/kg)
Trial: 36136377
Drug: Music Imagery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Imagery (8-weekly, individual sessions)
Trial: 36136794
Drug: Confidence in
RxNorm normalized name: miconazole nitrate Topical Cream [Clearly Confident]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confidence in the treatment
Trial: 36137526
Drug: MicroShunt implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MicroShunt implantation with adjunctive use of mitomycin C (0.2-0.4 mg/mL applied for 2-3 min)
Trial: 36137752
Drug: MICs infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MICs infusion before kidney transplantation
Trial: 36137752
Drug: MICs infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MICs infusion (highest dose) 7 days before surgery
Trial: 36137752
Drug: MICs infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MICs infusion (highest dose)
Trial: 36137752
Drug: MICs infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MICs infusion
Trial: 36138362
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without immunotherapy
Trial: 36139910
Drug: 10.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 g mixture of trehalose, spermidine, nicotinamide, and polyphenols
Trial: 36143102
Drug: Vitamin-K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K antagonists (VKA)
Trial: 36143102
Drug: Both antiplatelets
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both antiplatelets and oral anticoagulation
Trial: 36143388
Drug: Continuous amnioinfusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous amnioinfusion with Amnion Flush Solution (up to 100 mL/h, 2400 mL/day)
Trial: 36143388
Drug: Standard PPROM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PPROM therapy (antibiotics and corticosteroids)
Trial: 37928895
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus chemotherapy (NC)
Trial: 36149737
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Trial: 36149832
Drug: Darvadstrocel (24-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darvadstrocel (24-mL intralesional injection, 120×106 cells)
Trial: 36150050
Drug: Enasidenib 100mg
RxNorm normalized name: ENASIDENIB 100MG TAB
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enasidenib 100mg daily
Trial: 36150050
Drug: Enasidenib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib maintenance therapy
Trial: 36150143
Drug: Valemetostat 200
RxNorm normalized name: tazemetostat 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valemetostat 200 mg/day orally until progressive disease or unacceptable toxicity
Trial: 36150668
Drug: SARS-CoV-2 vaccine
RxNorm normalized name: SARS-CoV-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccine (CoronaVac) administered in two doses (28-days interval) with a booster at day 210.
Trial: 38609322
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors (TNFi)
Trial: 36150668
Drug: SSZ+TNFi combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSZ+TNFi combination
Trial: 36150668
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of vaccine (D69-D240)
Trial: 36151335
Drug: Appropriate empiric
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate empiric therapy
Trial: 36151773
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in combination with VIT (vincristine, irinotecan, and temozolomide) at Dose Level 4 (1666 mg/m2)
Trial: 36151773
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in combination with VIT
Trial: 36152144
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day)
Trial: 36152902
Drug: Thoracic Spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic Spinal Nerve Neuromodulation Therapy
Trial: 36152897
Drug: Anti-tumor necrosis
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tumor necrosis factor agents
Trial: 36155150
Drug: Plasma l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma l-carnitine
Trial: 36155150
Drug: Plasma l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma l-carnitine (highest tertile)
Trial: 36155490
Drug: Antiangiogenic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic agents (sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab)
Trial: 36155490
Drug: Chemotherapy based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy based regimens
Trial: 36155490
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with anti-PD-1/PD-L1 or anti-CTLA4 antibodies
Trial: 36156099
Drug: Epacadostat 100
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat 100 mg orally twice daily with pembrolizumab 200 mg intravenously every 3 weeks and one of 7 chemotherapy regimens
Trial: 36156099
Drug: Epacadostat 100
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat 100 mg orally twice daily with pembrolizumab and chemotherapy
Trial: 36158588
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy with resin yttrium-90 microspheres (SIRT) followed by gemcitabine 1,000 mg/m²
Trial: 36158690
Drug: Cytokine-induced killer
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy (etoposide plus platinum) followed by sintilimab maintenance treatment
Trial: 36158690
Drug: Sintilimab maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab maintenance treatment
Trial: 36161320
Drug: lovo-cel gene
RxNorm normalized name: Lovo-cel
DrugBank: Lovotibeglogene autotemcel (DB18680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovo-cel gene therapy (bb1111; LentiGlobin)
Trial: 36710205
Drug: Short-term androgen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term androgen deprivation therapy (ADT)
Trial: 36162011
Drug: CMV-specific immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV-specific immunoglobulins (CMV-Ig) administered to 10 patients in addition to standard antiviral prophylaxis.
Trial: 36162011
Drug: Standard antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiviral prophylaxis without CMV-Ig administered to 39 patients.
Trial: 36163163
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin (area under the curve 2) and weekly paclitaxel 80 mg/m2 in cohort 1 (triple-negative)
Trial: 36163163
Drug: Cyclophosphamide and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide and/or paclitaxel in cohort 2 (hormone receptor-positive)